vimarsana.com
Home
Live Updates
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review : vimarsana.com
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also...
Related Keywords
United States
,
American
,
Vesna Tosic
,
Tammy Allen
,
Nasdaq
,
American Society Of Hematology Annual Meeting
,
Regeneron Pharmaceuticals Inc
,
European Medicines Agency
,
Drug Administration
,
Exchange Commission
,
Linkedin
,
Odronextamab Clinical Program
,
Regeneron Genetics Center
,
Regeneron Approach To Cancer Research
,
Medicines Agency
,
Marketing Authorization
,
Priority Review
,
Biologics License Application
,
American Society
,
Hematology Annual
,
Orphan Drug Designation
,
Fast Track Designation
,
Marketing Authorization Application
,
Odronextamab Clinical
,
Lugano Classification
,
Regeneron Genetics
,
Looking Statements
,
Regeneron Pharmaceuticals
,
Product Candidates
,
Markets
,
vimarsana.com © 2020. All Rights Reserved.